LLY
Eli Lilly and Company
LLY has the edge over STAA overall, supported by lower modeled downside and stronger modeled upside.
STAA
STAAR Surgical Company
STAA's outlook is improving despite an expensive valuation.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STAA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
STAA's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over STAA in the historical PE scenario, which offers more potential upside but is not a forecast.
STAA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 50x | $26.78 | — |
| Cheap | 82x | $0.82 | -97% |
| Fair | 132x | $1.32 | -95% |
| Expensive | 350x | $3.50 | -87% |
| Current | 2,678x | $26.78 | — |
Historical ranges are pointers, not guarantees.
STAA's PE is in its expensive range at 2678x. If earnings grow as analysts expect, today's price would be 50x next year's earnings, in its cheap range.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over STAA on the outlook, with more favorable profitability expectations.
STAA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for STAA, with profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STAA on earnings, with more consistent year-over-year improvement.
STAA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.54 | +5306% |
| Q3 2026 | $0.01 | +$1.96 |
| Q2 2026 | $0.08 | +$2.01 |
| Q1 2026 | -$0.42 | +$1.02 |
| Q4 2025 | -$1.62 | -$1.21 |
| Q3 2025 | -$1.95 | -543% |
| Q2 2025 | -$1.93 | -668% |
| Q1 2025 | -$1.44 | -565% |
| Q4 2024 | -$0.41 | -195% |
STAA has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STAA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STAA on profitability, with a higher operating margin.
STAA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.4M | -12% |
| Q2 2026 | $93.5M | +111% |
| Q1 2026 | $93.5M | +120% |
| Q4 2025 | $57.8M | +18% |
| Q3 2025 | $94.7M | +6.9% |
| Q2 2025 | $44.3M | -55% |
| Q1 2025 | $42.6M | -45% |
| Q4 2024 | $49M | -36% |
STAA's revenue is growing: $83M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.5% | -13 points |
| Q2 2026 | 11% | +78 points |
| Q1 2026 | 8.5% | +143 points |
| Q4 2025 | -40% | +18 points |
| Q3 2025 | 20% | +13 points |
| Q2 2025 | -68% | -80 points |
| Q1 2025 | -135% | -132 points |
| Q4 2024 | -57% | -71 points |
STAA's operating margin was 6.5% last quarter, down 13 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over STAA on cash flow, with more consistent year-over-year improvement.
STAA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | +1379% |
| Q2 2026 | $19.2M | +$48.2M |
| Q1 2026 | -$22.1M | -$14.9M |
| Q4 2025 | -$5.6M | -$508K |
| Q3 2025 | $1.8M | +$4.2M |
| Q2 2025 | -$29M | -$12.4M |
| Q1 2025 | -$7.2M | -144% |
| Q4 2024 | -$5.1M | -118% |
STAA's free cash flow has turned positive after three years mostly in the red: $18M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STAA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STAA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -52K shares |
| 1 year | +1.8% | +900K shares |
| 3 years | +4.2% | +2.1M shares |
| 5 years | +3.7% | +1.9M shares |
| Available history | +9.7% | +4.6M shares |
STAA has 51M diluted shares, up 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | $2M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STAA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -13.9x | Net Cash |
| Q2 2026 | -6.7x | Net Cash |
| Q3 2024 | -5.2x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
| Q1 2023 | -2.3x | Net Cash |
| Q4 2022 | -1.8x | Net Cash |
| Q3 2022 | -2.4x | Net Cash |
| Q2 2022 | -4.2x | Net Cash |
STAA has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STAA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.9 | Neutral |
| Stochastic | 69.4 | Neutral |
STAA's weekly RSI is 58 (neutral) and its Stochastic is 69 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over STAA on valuation relative to its sector.
STAA PE vs Healthcare Sector
| Metric | STAA | Sector median | Relative |
|---|---|---|---|
| PE | 2,678x | 26x | 10,260% above |
| PE % | 100 | 29 | 71 pts above |
STAA is trading at 2678x earnings, a 10260% premium to the Healthcare sector's median of 26x.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STAA on trend strength, trading above more of its moving averages.
STAA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.1 | 16% above |
| 20 week MA | $23.9 | 12% above |
| 50 week MA | $23.7 | 13% above |
| 100 week MA | $22.8 | 18% above |
| 200 week MA | $33.3 | 19% below |
STAA has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 19% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STAA on returns for 2026, with the stronger performance.
STAA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.5 | $81.4 | +123% |
| 2021 | $81.4 | $96.3 | +18% |
| 2022 | $96.3 | $48.4 | -50% |
| 2023 | $48.4 | $31.2 | -36% |
| 2024 | $31.2 | $24.2 | -22% |
| 2025 | $24.2 | $23.4 | -3.6% |
| 2026 YTD | $23.4 | $26.8 | +15% |
STAA has finished four years in a row lower, and it's up 15% so far in 2026.